Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.55 |
| ▸ | CNR1 | P21554 | 2/20 | 0.55 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.41 |
| ▸ | RHOC | P08134 | 1/20 | 0.41 |
| ▸ | RHOA | P61586 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411579 | 0.85 | CNR2 (0.56) | CNR2CNR1PTGER1TP53THRB | |
| SCHEMBL412287 | 0.80 | CNR2 (0.56) | CNR2CNR1PTGER1RHOCRHOA | |
| SCHEMBL411128 | 0.80 | CNR2 (0.60) | CNR2CNR1PTGER1RHOCRHOA | |
| SCHEMBL412269 | 0.79 | CNR2 (0.56) | CNR2CNR1PTGER1 | |
| SCHEMBL412264 | 0.79 | CNR2 (0.56) | CNR2CNR1PTGER1RHOCRHOA | |
| SCHEMBL412268 | 0.79 | RHOC (0.41) | CNR2CNR1RHOCRHOATP53 | |
| SCHEMBL411155 | 0.78 | CNR1 (0.62) | CNR2CNR1 | |
| SCHEMBL410643 | 0.76 | CNR2 (0.43) | CNR2CNR1RHOCRHOATP53 | |
| SCHEMBL411043 | 0.74 | CNR2 (0.66) | CNR2CNR1PTGER1 | |
| SCHEMBL412054 | 0.74 | CNR2 (0.43) | CNR2CNR1RHOCRHOATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | claimed |
| EP-2613785-B1 | HETEROARYLMETHYL AMIDES | HOFFMANN LA ROCHE (CH) | 2015-07-29 | — | — | EP | disclosed |
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8729105-B2 | Heteroarylmethyl amides | HOFFMANN LA-ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729105-B2 | Heteroarylmethyl amides | HOFFMANN LA-ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | CNR2 435/4885CNR1 269/4885PTGER1 676/4885 |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | CNR2 435/4885CNR1 269/4885PTGER1 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.